<DOC>
	<DOCNO>NCT01502345</DOCNO>
	<brief_summary>The purpose study : • To assess safety tolerability HTNV PUUV DNA vaccine , pWRG/HTN-M ( x ) pWRG/PUUV-M ( s2 ) , administer intramuscularly use TDS-IM electroporation device Secondary : • To evaluate clinical immunogenicity HTNV PUUV DNA vaccine , pWRG/HTN-M ( x ) pWRG/PUUV-M ( s2 ) , include assessment acute procedure tolerability administer TDS-IM electroporation .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Immunogenicity Hantaan Puumala Virus DNA Vaccines</brief_title>
	<detailed_description>The study enroll 3 randomized group 9 subject , along 3 alternate , total 30 subject . The study include one group subject inject HTNV DNA vaccine , one group inject PUUV DNA vaccine , one group inject HTNV PUUV DNA vaccine ( mixed ) , administer Ichor TDS-IM device . Subjects receive one dose vaccine Days 0 , 28 , 56 follow Day 240 . Subjects complete post-injection memory aid 14 day injection . Subjects evaluate safety immune response throughout study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Hemorrhagic Fever Renal Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male nonpregnant , nonlactating female , age 1849 ( inclusive ) time screen Have demonstrate adequate comprehension protocol , achieve score least 80 % correct short multiplechoice quiz Individuals fail achieve passing score initial quiz give opportunity retest review protocol information Individuals fail comprehension assessment second time enrol Have provide write informed consent screen Free clinically significant health problem , determine pertinent medical history clinical examination entry study Available able participate study visit procedure If sexually active , know least 1 year postmenopausal , willing use effective method contraception ( e.g. , birth control pill , diaphragm , cervical cap , intrauterine device , condom , anatomical sterility [ self partner ] ) date screen least 6 month last vaccination Negative hantavirus IgG antibody test result screening ( ELISA ) History serologic evidence prior infection either HTNV PUUV virus , prior participation HTNV PUUV virus vaccine trial History severe local systemic reaction vaccination history severe allergic reaction Any serologic evidence hepatitis B C infection Ongoing participation another clinical trial Receipt plan receipt vaccination , experimental otherwise , within period 30 day prior initial injection 60 day Day 70 followup ( approximately 6 month period total ) Individuals skinfold measurement cutaneous subcutaneous tissue eligible injection site ( deltoid region ) exceed 40 mm Individuals ability observe possible local reaction eligible injection site ( deltoid region ) , opinion investigator , unacceptably obscure due physical condition permanent body art Acute chronic , clinically significant hematologic , pulmonary , cardiovascular , hepatic renal functional abnormality determine investigator base medical history , physical examination , EKG , and/or laboratory screen test Pregnant lactate female , female intend become pregnant study period Administration immunoglobulins and/or blood product within 120 day precede study entry plan administration study period Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month study entry For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day Inhaled topical steroid allow Any chronic active neurologic disorder , include seizure epilepsy , exclude single febrile seizure child Syncopal episode within 12 month screen Suspected known current alcohol abuse define American Psychiatric Association DSM IV ( Diagnostic Statistical Manual Mental Disorders4th edition ) Chronic active illicit and/or intravenous drug use Unwilling allow storage use blood future hantavirusrelated research Any significant finding opinion investigator would increase risk individual adverse outcome participating study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HFRS</keyword>
</DOC>